Skip to main content
SpringerLink
Log in

ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary?

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.

    Article  PubMed  Google Scholar 

  2. Kato H, Usui M, Isaji S, et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:601–10.

    Article  PubMed  Google Scholar 

  3. Murakami Y, Satoi S, Sho M, et al. National comprehensive cancer network resectability status for pancreatic carcinoma predicts overall survival. World J Surg. 2015;39:2306–14.

    Article  PubMed  Google Scholar 

  4. Takahashi H, Akita H, Tomokuni A, et al. Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer: impact of venous and arterial involvement status on surgical outcome and pattern of recurrence. Ann Surg. 2016;264:1091–7.

    Article  PubMed  Google Scholar 

  5. Nagakawa Y, Hosokawa Y, Nakayama H, et al. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. Cancer Chemother Pharmacol. 2017;79:951–7.

    Article  CAS  PubMed  Google Scholar 

  6. Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol. Epub 4 Jan 2019. https://doi.org/10.1245/s10434-018-07131-8.

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Shinjuku, Tokyo, Japan

    Yuichi Nagakawa MD, PhD, FACS

Authors
  1. Yuichi Nagakawa MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuichi Nagakawa MD, PhD, FACS.

Ethics declarations

Disclosures

Yuichi Nagakawa has no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ASO Author Reflections is a brief invited commentary on the article, “Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery”, Ann Surg Oncol. Epub 4 Jan 2019.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagakawa, Y. ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary?. Ann Surg Oncol 26, 1637–1638 (2019). https://doi.org/10.1245/s10434-019-07245-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07245-7

Search

Navigation